Kite Pharma, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Cash flows from operating activities
Net loss
Adjustment to reconcile net loss to net cash from operating activities
Depreciation and amortization
Stock-based compensation
Noncash interest expense
Deferred tax
Restricted cash
Fair value adjustment of contingent consideration
Amortization on marketable securities
Loss related to equity method investment
Other
Changes in operating assets and liabilities
Deferred revenue
Deferred rent
Loss on disposal of assets
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses and other current liabilities
Due to related parties
Capital expenditures
Net cash used in operating activities
Cash flows from investing activities
Purchase of property and equipment
Purchases of marketable securities
Sales and maturities of marketable securities
Cash paid for equity investment in Cell Design Labs
Net cash paid related to acquisition
Net cash used in investing activities
Cash flows from financing activities
Principal payments on capital lease obligations
Payment of contingent consideration
Initial public offering costs
Proceeds from issuance of common stock
Proceeds from exercise of stock options
Proceeds from employee stock purchase plan
Proceeds from issuance of convertible notes
Net cash provided by financing activities
Effect of exchange rate changes on cash
Net change in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental schedule of cash flows information:
Cash paid for interest
Proceeds from employee stock plan received in advance of issuance
Supplemental schedule of non-cash investing and financing activities:
Conversion of convertible notes and accrued interest into equity
Discount from conversion of securities convertible into equity
Conversion of convertible securities into equity
Employee stock purchase plan shares issued
Tenant improvement allowance receivable
Issuance of stock to purchase T-Cell Factory, B.V.
T-Cell Factory Acquisition
Total issuance of stock to purchase T-Cell Factory, B.V.

Comments